RT Journal Article
T1 Mimicking chronic glaucoma over 6 months with a single intracameral injection of dexamethasone/fibronectin-loaded PLGA microspheres
A1 Aragón Navas, Alba
A1 Rodrigo, Maria Jesus
A1 García Herranz, David
A1 Martínez, Teresa
A1 Subías, Manuel
A1 Mendez, Silvia
A1 Ruberte, Jesús
A1 Pampalona, Judit
A1 Bravo Osuna, Irene
A1 García Feijoo, Julián
A1 Pablo, Luis E
A1 García Martín, Elena Salobrar
A1 Herrero Vanrell, María Del Rocío
AB To create a chronic glaucoma animal model by a single intracameral injection of biodegradable poly lactic-co-glycolic acid (PLGA) microspheres (Ms) co-loaded with dexamethasone and fibronectin (MsDexaFibro). MsDexaFibro were prepared by a water-in-oil-in-water emulsion method including dexamethasone in the organic phase and fibronectin in the inner aqueous phase. To create the chronic glaucoma model, an interventionist and longitudinal animal study was performed using forty-five Long Evans rats (4-week-old). Rats received a single intracameral injection of MsDexafibro suspension (10%w/v) in the right eye. Ophthalmological parameters such as clinical signs, intraocular pressure (IOP), neuro-retinal functionality by electroretinography (ERG), retinal structural analysis by optical coherence tomography (OCT), and histology were evaluated up to six months. According to the results obtained, the model proposed was able to induce IOP increasing in both eyes over the study, higher in the injected eyes up to 6 weeks (p < 0.05), while preserving the ocular surface.OCT quantified progressive neuro-retinal degeneration (mainly in the retinal nerve fiber layer) in both eyes but higher in the injected eye. Ganglion cell functionality decreased in injected eyes, thus smaller amplitudes in PhNR were detected by ERG. In conclusion, a new chronic glaucoma animal model was created by a single injection of MsDexaFibro very similar to open-angle glaucoma occurring in humans. This model would impact in different fields such as ophthalmology, allowing long period of study of this pathology; pharmacology, evaluating the neuroprotective activity of active compounds; and pharmaceutical technology, allowing the correct evaluation of the efficacy of long-term sustained ocular drug delivery systems.
PB Taylor and Francis
SN 1071-7544
YR 2022
FD 2022-07-29
LK https://hdl.handle.net/20.500.14352/73112
UL https://hdl.handle.net/20.500.14352/73112
LA eng
NO Instituto de Salud Carlos III
NO Ministerio de Ciencia, Innovación y Universidades (España)
DS Docta Complutense
RD 4 abr 2025